| Not Yet Recruiting | Long-term Study to Evaluate Safety and Persistence of GF-CART01 NCT06985576 | GenomeFrontier Therapeutics TW Co., Ltd. | — |
| Recruiting | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363 | University of Washington | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Recruiting | Immunotherapy in Lymphoma NCT06796517 | Sung-Soo Park | — |
| Not Yet Recruiting | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment NCT06412068 | Sun Yat-sen University | Phase 2 |
| Recruiting | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19 NCT06238648 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Pembro Plus CAR T-cell Therapy in R/R in PMBCL NCT05934448 | Jennifer Crombie, MD | Phase 2 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Recruiting | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy NCT05377307 | Pell Bio-Med Technology Co., Ltd. | — |
| Recruiting | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell NCT05326243 | Pell Bio-Med Technology Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-C NCT04759586 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) NCT04824950 | Centre Henri Becquerel | N/A |
| Terminated | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies NCT04844086 | Eden BioCell Ltd. | Phase 1 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Unknown | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL NCT04705129 | Ruijin Hospital | Phase 2 |
| Withdrawn | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity NCT04503538 | Wake Forest University Health Sciences | N/A |
| Recruiting | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Agg NCT04231877 | University of Washington | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell NCT04542824 | Genmab | Phase 1 / Phase 2 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Active Not Recruiting | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia NCT04323657 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Terminated | LITT and Pembrolizumab in Recurrent Brain Metastasis NCT04187872 | University of Florida | Phase 1 |
| Completed | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma NCT04833504 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell NCT04067414 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Unknown | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs NCT03346642 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Withdrawn | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DL NCT02653989 | Medivation, Inc. | Phase 2 |
| Completed | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lym NCT01965119 | Samsung Medical Center | Phase 2 |
| Completed | A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL NCT02423291 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone NCT01897571 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Completed | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituxima NCT01516567 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | CT-011 MAb in DLBCL Patients Following ASCT NCT00532259 | CureTech Ltd | Phase 2 |
| Completed | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lympho NCT00001337 | National Cancer Institute (NCI) | Phase 2 |